The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results ...

Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...

Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company’s ...

Fintel reports that on March 21, 2025, Cantor Fitzgerald initiated coverage of GlycoMimetics (NasdaqCM:GLYC) with a ...

Following up on this discovery, the researchers investigated whether CXCL12 is involved in the recruitment of CD8+ cells by blocking the corresponding receptor (CXCR4) for this signaling protein ...

3 The selective CXC chemokine receptor 4 (CXCR4) antagonist was designed to increase the number of circulating mature neutrophils and lymphocytes to address the pathway dysfunction causing the ...

Figure 2. ACKR3 exhibits greater conformational flexibility compared to CXCR4. A) Apparent FRET efficiency histogram of apo-CXCR4 (left, black trace) resolved into three distinct conformational states ...

The chemokine receptor CXCR4 and its ligand CXCL12 play an important homeostatic function by mediating the homing of progenitor cells in the bone marrow and regulating their mobilization into ...

The canonical chemokine receptor CXCR4 and atypical receptor ACKR3 both respond to CXCL12 but induce different effector responses to regulate cell migration. While CXCR4 couples to G proteins and ...